Part 5: From Lab to Clinic: Preparing MT1988 For Its First Patient Trial
In our last post, we explored the scientific rationale behind MT1988 and how the history of nicotinic receptor research has shaped its design. In this post we shift gears from why MT1988 matters, to how it has progressed from concept to clinical reality as it enters evaluation in a clinical high risk (CHR) for psychosis […]
Part 4: The History and Science Behind MT1988
In our last post, we introduced the team leading the MT1988 proof-of-principle clinical trial – a major collaboration under the AMP® SCZ programme focused on accelerating early intervention in individuals at clinical high risk (CHR) for psychosis. This week, we explore the science behind MT1988 – its mechanism of action as a nicotinic agonist, how […]
Part 3: Meet the Team Advancing Early Intervention in Psychosis
In our last post, we explored how the clinical high risk (CHR) for psychosis stage can reveal the earliest cognitive and neurobiological impairments linked to psychosis risk, offering an important opportunity to evaluate treatments aligned with those mechanisms. This week, we introduce the scientific and clinical leaders who are driving that work forward through our […]
Part 2: Why CHR Matters – Advancing Early Intervention Through Precision Psychiatry
In our last post, we discussed how precision psychiatry is transforming neuroscience drug development by aligning treatments with the biological mechanisms that drive symptoms. This week, we turn our focus to a key population in that paradigm: people at clinical high risk (CHR) for psychosis. Understanding CHR: The Window of Opportunity Psychotic disorders such as […]
Part 1: Changing the Odds with Precision Psychiatry
Over the last decade, the prevalence of psychiatric disorders has increased by roughly 50% and today’s approved medicines only help about half of the patients who take them. The need for better treatment options for disorders such as depression, schizophrenia and ADHD is therefore substantial, yet approximately 95% of neuroscience drug candidates fail in clinical […]
Introducing ‘FROM SYMPTOMS TO SIGNALS: A New Era in Psychiatry’
Introducing From Symptoms to Signals For decades, psychiatric research has been grounded in symptoms – what patients describe and what clinicians observe. Symptom checklists and interviews have been the foundation of diagnosis, treatment decisions, and the primary yardstick for measuring success in clinical trials. We are now entering a new era. Advances in neuroscience and […]